Advances in Anti-Osteoporosis Polysaccharides Derived from Medicinal Herbs and Other Edible Substances

2022 ◽  
pp. 1-30
Author(s):  
Zefeng Zhao ◽  
Meng Nian ◽  
Hong Lv ◽  
Jiangxin Yue ◽  
Haifa Qiao ◽  
...  
Keyword(s):  
Osteoporotic Fractures ◽  
Fragility Fractures ◽  
Extraction Methods ◽  
Medicinal Herbs ◽  
Osteoporosis Therapy ◽  
Metabolic Bone ◽  
Anabolic Action ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Sar Analysis

Osteoporosis is a common metabolic bone disease, and treatment is required for the pre-vention of low bone mass, deterioration of microstructural bone tissue, and fragility fractures. Osteoporosis therapy includes calcium, vitamin D, and drugs with antiresorptive or anabolic action on the bone. Therapy for osteoporosis does not include taking non-steroidal anti-inflammatory drugs (NSAID), but pain associated with osteoporotic fractures can be treated by taking non-steroidal anti-inflammatory drugs (NSAID). Recently, polysaccharides extracted from medicinal herbs and edible substances (PsMHES) have attracted attention on account of their safety and promising anti-osteoporosis effects, whereas a systematic review about their potential in anti-osteoporosis is vacant to date. Herein, we reviewed the recent progress of PsMHES with anti-osteoporosis activities, looking to introduce the advances in the various pharmacological mechanisms and targets involved in the anti-osteoporosis effects, extraction methods, main mechanism involved in Wnt/β-catenin pathways and pathways and RANKL (Receptor Activator for NFκB ligand or TNFSF25) pathways, and Structure-Activity elationships (SAR) analysis of PsMHES. Typical herbs like Achyranthes bidentate and Morinda officinalis used for the treatment of osteoporosis are introduced; their traditional uses in traditional Chinese medicine (TCM) are discussed in this paper as well. This review will help to the recognition of the value of PsMHES in anti-osteoporosis and provide guidance for the research and development of new anti-osteoporosis agents in clinic.

scholarly journals Menopausal osteoporosis in the practice of a gynecologist

2021 ◽  
pp. 320-331
Author(s):  
I. V. Kuznetsova ◽  
R. A. Chilova
Keyword(s):  
At Risk ◽  
Osteoporotic Fractures ◽  
Fragility Fractures ◽  
Risk Groups ◽  
Health Examination ◽  
Bolus Administration ◽  
Mineral Density ◽  
Osteoporosis Therapy ◽  
Antiresorptive Agents ◽  
Increased Risk

Osteoporosis represents a great healthcare challenge due to an increased risk of fragility fractures that significantly decreases quality of life, shortens life expectancy, and looms as an onerous burden on both the social environment of patients and society as a whole. Osteoporotic fractures can’t be prevented without early diagnosis of low bone mineral density in people at risk. Unfortunately, the population at risk of osteoporosis is not covered by the periodic health examination program in real practice, and involving doctors of different specialties in the prevention and treatment of this disease is one of the options for addressing the challenge. As the risk of osteoporosis is associated with age and estrogen deficiency in women, the gynecologist can and should assume responsibility for the formation of risk groups, monitoring and timely recommendations on preventive and therapeutic actions. The gynecologist’s possibilities should not be reduced solely to recommendations for correcting lifestyle and prescribing menopausal hormone therapy. Antiresorptive agents of the first-line osteoporosis therapy may also be included in the gynecologist’s drug arsenal. Among them are the most commonly used bisphosphonates that are characterized by a good efficacy and safety profile during the long-term use. However, oral administration of bisphosphonates is associated with low compliance due to adverse reactions and the need for strict observance of the rules for their administration. In contrast, intravenous administration of bisphosphonates improves compliance and allows to ensure the optimal treatment outcome. Ibandronate intended for intravenous bolus administration once every three weeks for 5 years is one of the possibilities of using parenteral bisphosphonate therapy in the practice of gynecology. 

scholarly journals Use of nonsteroidal anti-inflammatory drugs in patients with vertebral osteoporotic fractures

Reumatismo ◽  
2011 ◽  
Vol 54 (4) ◽  
Author(s):  
M. Rossini ◽  
F. Bertoldo ◽  
R. Lovato ◽  
R. Bortolotti ◽  
D. Gatti ◽  
...  
Keyword(s):  
Osteoporotic Fractures ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Polyphenols from Cymbopogon citratus inhibit iNOS expression and NO production – a promising source of new anti-inflammatory drugs

Planta Medica ◽  
2010 ◽  
Vol 76 (12) ◽  
Author(s):  
V Francisco ◽  
A Figueirinha ◽  
B Neves ◽  
C Garcia-Rodriguez ◽  
M Lopes ◽  
...  
Keyword(s):  
Inos Expression ◽  
No Production ◽  
Cymbopogon Citratus ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Promising Source

Heparin and proteoglycans as anti-inflammatory drugs

1996 ◽  
Vol 16 (01) ◽  
pp. 56-59
Author(s):  
D. J. Tyrrell ◽  
C. P. Page
Keyword(s):  
Inflammatory Diseases ◽  
Therapeutic Applications ◽  
Wide Range ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

SummaryEvidence continues to accumulate that the pleiotropic nature of heparin (beyond its anticoagulant potency) includes anti-inflammatory activities at a number of levels. It is clear that drugs exploiting these anti-inflammatory activities of heparin may offer exciting new therapeutic applications to the treatment of a wide range of inflammatory diseases.

Non-Steroidal Anti-inflammatory Drugs (NSAIDs): Synthesis of Ibuprofen, Naproxen and Nabumetone

2019 ◽  
pp. 19-27
Keyword(s):  
Review Paper ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Synthetic Approaches

This review paper covers the major synthetic approaches attempted towards the synthesis of some Non-Steroidal Anti-Inflammatory Drugs (Naproxen, Ibuprofen and Nabumetone)

Sign in / Sign up

Export Citation Format

Share Document